🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,760 results for “Pharm” Clear

  1. PROPRANOLOL

    Pari Pharma GmbH

    Von Hippel-Lindau (VHL) disease

    phase 3 small molecule active

    1 trial

  2. PROTAMINE CHOAY 1000 U.A.H./ml, solution injectable

    Pari Pharma GmbH

    Any patients ≥18 years old, eligible for transfemoral TAVI with coverage for medical insurance

    phase 3 small molecule active

    1 trial

  3. PROVIGIL 200 mg

    Teva Pharma GmbH

    Chronic Shift Work Sleep Disorder

    phase 3 small molecule completed

    1 trial

  4. PV-10 (10% rose bengal disodium)

    PROVECTUS BIOPHARMACEUTICALS, INC.

    Cutaneous Melanoma

    phase 3 small molecule terminated

    1 trial

  5. Paclitaxel 6 mg/ml Concentrate for Solution for Infusion, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Armisarte 25 mg/ml concentrate for solution for infusion, YERVOY 5 mg/ml concentrate for solution for infusion, Carboplatin 10 mg/ml concentrate for solution for infusion, LIBTAYO 350 mg concentrate for solution for infusion.

    Lacuna Pharma Pty Ltd

    Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  6. Paclitaxel Ribosepharm 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Abraxane 5 mg/ml powder for dispersion for infusion., Carboplatin 10 mg/ml concentrate for solution for infusion, Pazenir 5 mg/ml powder for dispersion for infusion, ivonescimab, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Summit Therapeutics

    Metastatic Squamous Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  7. Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine

    Teva Pharma GmbH

    Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

    phase 3 small molecule completed

    1 trial

  8. Palazestrant

    Olema Pharmaceuticals

    Breast Cancer

    phase 3 small molecule active

    3 trials

  9. Palazestrant matching placebo tablets and Letrozole matching placebo capsules, Palazestrant, RIBOCICLIB, Palazestrant, -, LETROZOLE , Palazestrant

    Olema Pharmaceuticals

    ER+, HER2- Advanced Breast Cancer

    phase 3 small molecule active

    1 trial

  10. Palazestrant, FULVESTRANT, Palazestrant, EXEMESTANE, GOSERELIN , LETROZOLE, Palazestrant, Palazestrant, ANASTROZOLE

    Olema Pharmaceuticals

    ER+, HER2- metastatic breast cancer following endocrine and CDK 4/6 inhibitor therapy

    phase 3 small molecule active

    1 trial

  11. Paltusotine

    Crinetics Pharmaceuticals Europe GmbH

    Acromegaly

    phase 3 small molecule active

    5 trials

  12. Paltusotine

    Crinetics Pharmaceuticals Europe GmbH

    Carcinoid Syndrome

    phase 3 small molecule active

    1 trial

  13. Palynziq 2.5 mg solution for injection in pre-filled syringe, Palynziq 20 mg solution for injection in pre-filled syringe, Palynziq 10 mg solution for injection in pre-filled syringe

    BioMarin Pharmaceutical Australia Pty Ltd

    Phenylketonuria (PKU)

    phase 3 small molecule active

    1 trial

  14. Panobinostat

    Novartis Pharmaceuticals

    Multiple Myeloma

    phase 3 small molecule completed

    1 trial

  15. Paracetamol/Ibuprofen Vale 1000 mg/300 mg oldatos infúzió

    Lacuna Pharma Pty Ltd

    Acute pain

    phase 3 small molecule active

    1 trial

  16. Part A: Upamostat 200 mg

    RedHill Biopharma

    Covid19

    phase 3 small molecule terminated

    1 trial

  17. Participants will receive one dose of vaccine (0.5 mL) of Sinovac QIV

    Biotech Pharmaceutical Co.,

    Influenza

    phase 3 mab active

    1 trial

  18. Pegvaliase

    BioMarin Pharmaceutical Australia Pty Ltd

    Phenylketonuria (PKU)

    phase 3 small molecule active

    2 trials

  19. Pegylated Interferon Alfa 2a

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C

    phase 3 mab completed

    1 trial

  20. Pegylated Interferon Alfa 2a

    Vertex Pharmaceuticals (Australia) Pty.

    Infection

    phase 3 small molecule terminated

    1 trial

  21. Pelacarsen

    Novartis Pharmaceuticals

    Atherosclerotic Cardiovascular Disease (ASCVD)

    phase 3 small molecule active

    1 trial

  22. Permethrin, InfectoScab® 5 % Crème

    Alphapharm Pty Ltd

    Scabies

    phase 3 small molecule active

    1 trial

  23. Phase 2; Low Dose MYOBLOC

    SUPERNUS PHARMACEUTICALS, INC.

    Spasticity

    phase 3 small molecule active

    1 trial

  24. Phase 2; Low Dose MYOBLOC (15,000 Units)

    SUPERNUS PHARMACEUTICALS, INC.

    Spasticity

    phase 3 small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources